Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Medical Plaza
# 365C
Los Angeles, CA 90095Phone+1 310-206-7663Fax+1 310-206-1609
Education & Training
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1993 - 1997
- NYU Grossman School of MedicineResidency, Internal Medicine, 1990 - 1993
- The Warren Alpert Medical School of Brown UniversityClass of 1990
Certifications & Licensure
- CA State Medical License 2000 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Specimen Repository for HIV Immunopathogenesis Start of enrollment: 2017 Jul 31
- Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection Start of enrollment: 2020 Apr 17
- Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection Start of enrollment: 2017 May 01
- Join now to see all
Publications & Presentations
PubMed
- 168 citationsGood's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.Theodoros Kelesidis, Otto O. Yang
Clinical Immunology. 2010-06-01 - 1155 citationsBaricitinib plus Remdesivir for Hospitalized Adults with Covid-19.Andre C. Kalil, Thomas F. Patterson, Aneesh K. Mehta, Kay M. Tomashek, Cameron R. Wolfe
The New England Journal of Medicine. 2021-03-04 - 28 citationsThe systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2.Suan-Sin Foo, Mary Catherine Cambou, Thalia Mok, Viviana M. Fajardo, Kyle L. Jung
Cell Reports. Medicine. 2021-10-27
Journal Articles
- Cross-Reactivity Against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte ClonesOtto Yang, MD, mBio
- Highly Attenuated Infection with a Vpr-Deleted Molecular Clone of HIV-1Peter A Anton, Jennifer A Fulcher, Otto O Yang, Joel N Blankson, The Journal of Infectious Diseases
Press Mentions
- Vaccines and Long COVID: What Do We Know?October 4th, 2024
- Here’s What to Know About the COVID-19 Summer SurgeAugust 30th, 2024
- Right Here's What to Know Concerning the COVID-19 Summer Time SurgeAugust 30th, 2024
- Join now to see all
Grant Support
- Translational AIDS And Viral Pathogenesis Training (51)National Institute Of Allergy And Infectious Diseases2010–2012
- HIV-1 Escape From Inhibition By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1999–2012
- Identifying And Closing GAPS In TCR Coverage Of HIV-1 EscapeNational Institute Of Allergy And Infectious Diseases2011
- Addressing Intra-/Inter-Clade Diversity In HIV Vaccine Design By Immune FocusingNational Institute Of Allergy And Infectious Diseases2010–2011
- Immune Pressure On HIV-1 Nef By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases2002–2011
- Mucosal And Peripheral NK-T Cells In HIV InfectionNational Institute Of Allergy And Infectious Diseases2006–2007
- HIV-1 Excape From Inhibiton By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases2003–2007
- HIV-1 Escape From Inhibition By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1998–1999
- Inhibition Of HIV 1 By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1996–1998
- Inhibition Of HIV-1 By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1995–1996
Research History
- ProfessorUCLA Medical School1999 - Present
- InstructorMassachusetts General Hospital, Harvard Medical School1997 - 1999
Other Languages
- Taiwanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: